{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:02:19Z","timestamp":1788836539201,"version":"build-2803163510"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The use of immune checkpoint inhibitors (ICI) can lead to immune-related adverse events (irAE), of which skin irAE is common, affecting up to 50% of ICI-treated patients. Although only a few cases of subacute cutaneous lupus erythematosus (SCLE) have been reported in patients receiving anti-programmed death-1(anti-PD-1) immunotherapy, it is important to identify ICI-induced SCLE because it may cause delayed and\/or prolonged skin reactions even after treatment discontinuation. To date, no cases of cutaneous lupus associated with Camrelizumab treatment have been reported.<\/jats:p><jats:sec><jats:title>Case report<\/jats:title><jats:p>We report a case of a patient with advanced non-small cell lung cancer (NSCLC) who gradually developed erythematous rashes on sun-exposed skin with pruritus after one course of anti-PD-1 antibody Camrelizumab combined with chemotherapy. The rashes were initially considered as eczema, but did not improve after symptomatic treatment. The rashes continued to worsen after the third course of treatment, and the pruritus was unbearable. After antibody testing, the patient was found to have positive anti-SS-A\/Ro antibody, and the histological changes were consistent with subacute cutaneous lupus erythematosus. SCLE was controlled with local and systemic glucocorticoids, hydroxychloroquine, and discontinuation of anti-PD-1 therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Camrelizumab treatment may be associated with the appearance of subacute cutaneous lupus erythematosus in sun-exposed skin regions, which can be rapidly relieved by local and systemic glucocorticoids and hydroxychloroquine. It is recommended to perform early antibody testing and skin biopsy for diagnosis and treatment. Unlike classic drug-related SCLE, patients may develop multiple autoimmune diseases, and caution should be taken when using immune checkpoint inhibitors for subsequent treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1539373","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T07:13:31Z","timestamp":1743146011000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Case Report: Subacute cutaneous lupus erythematosus induced by the anti-PD-1 antibody camrelizumab combined with chemotherapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Hejing","family":"Bao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiani","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hehong","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiazhu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shudong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.4318","article-title":"Management of cutaneous immune-related adverse events in patients with cancer treated with immune checkpoint inhibitors: A systematic review","volume":"8","author":"Nadelmann","year":"2022","journal-title":"JAMA Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.10110.x","article-title":"A systematic review of drug-induced subacute cutaneous lupus erythematosus","volume":"164","author":"Lowe","year":"2011","journal-title":"Br J Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14449","article-title":"De novo subacute cutaneous lupus erythematosus-like eruptions in the setting of programmed death-1 or programmed death ligand-1 inhibitor therapy: clinicopathological correlation","volume":"46","author":"Bui","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.04.105","article-title":"Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features","volume":"83","author":"Ellis","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.11.018","article-title":"Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-sq): A phase 3 trial","volume":"17","author":"Ren","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30365-9","article-title":"Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial","volume":"9","author":"Zhou","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.12836","article-title":"Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial","volume":"326","author":"Luo","year":"2021","journal-title":"JAMA"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00302-8","article-title":"Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial","volume":"22","author":"Yang","year":"2021","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S1470-2045(23)00531-4","article-title":"Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trial","volume":"25","author":"Li","year":"2024","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-4313","article-title":"Famitinib with camrelizumab and nab-paclitaxel for advanced immunomodulatory triple-negative breast cancer (FUTURE-C-plus): an open-label, single-arm, phase II trial","volume":"28","author":"Chen","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.1363","article-title":"Camrelizumab plus apatinib and temozolomide as first-line treatment in patients with advanced acral melanoma: the CAP 03 phase 2 nonrandomized clinical trial","volume":"9","author":"Mao","year":"2023","journal-title":"JAMA Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.2751","article-title":"Neoadjuvant camrelizumab plus platinum-based chemotherapy vs chemotherapy alone for chinese patients with resectable stage IIIA or IIIB (T3N2) non-small cell lung cancer: the TD-FOREKNOW randomized clinical trial","volume":"9","author":"Lei","year":"2023","journal-title":"JAMA Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.12.017","article-title":"Camrelizumab plus carboplatin and pemetrexed as first-line treatment for advanced nonsquamous NSCLC: extended follow-up of cameL phase 3 trial","volume":"18","author":"Zhou","year":"2023","journal-title":"J Thorac Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2022.09.005","article-title":"Cutaneous lupus erythematosus: a review of etiopathogenic, clinical, diagnostic and therapeutic aspects","volume":"98","author":"Vale","year":"2023","journal-title":"Bras Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00774-8","article-title":"Cutaneous lupus erythematosus: an update on pathogenesis and future therapeutic directions","volume":"24","author":"Niebel","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.04.150","article-title":"The history of lupus throughout the ages","volume":"87","author":"Felten","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3899\/jrheum.220089","article-title":"Cutaneous involvement in systemic lupus erythematosus: A review for the rheumatologist","volume":"50","author":"Stull","year":"2023","journal-title":"J Rheumatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17245","article-title":"Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy","volume":"181","author":"Marano","year":"2019","journal-title":"Br J Dermatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1324231","article-title":"Manifestation of subacute cutaneous lupus erythematosus during treatment with anti-PD-1 antibody cemiplimab - a case report","volume":"14","author":"Fietz","year":"2023","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1334718","article-title":"Immune checkpoint inhibitor-induced subacute cutaneous lupus erythematosus: a case report and review of the literature","volume":"11","author":"Khorasanchi","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000536","article-title":"Subacute cutaneous lupus erythematosus induced by nivolumab: two case reports and a literature review","volume":"29","author":"Zitouni","year":"2019","journal-title":"Melanoma Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13538","article-title":"Subacute cutaneous lupus erythematosus induced by PD-1 Inhibitor therapy: two case reports and literature review","volume":"62","author":"Diago","year":"2021","journal-title":"Australas J Dermatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijwd.2019.07.004","article-title":"Cutaneous lupus erythematosus: A review of the literature","volume":"5","author":"Blake","year":"2019","journal-title":"Int J Womens Dermatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2021.02.006","article-title":"Cutaneous drug-induced lupus erythematosus: Clinical and immunological characteristics and update on new associated drugs","volume":"148","author":"Bataille","year":"2021","journal-title":"Ann Dermatol Venereol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.10.054","article-title":"De novo cutaneous connective tissue disease temporally associated with immune checkpoint inhibitor therapy: A retrospective analysis","volume":"84","author":"Bui","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000587","article-title":"Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases","volume":"29","author":"Blakeway","year":"2019","journal-title":"Melanoma Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320983448","article-title":"Onset of subacute cutaneous lupus erythematosus after the initiation of immune checkpoint inhibitor therapy of cancer","volume":"30","author":"Gambichler","year":"2021","journal-title":"Lupus"},{"key":"B30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/CCID.S344445","article-title":"Subacute cutaneous lupus erythematosus-like eruption induced by durvalumab: A case report and literature review","volume":"15","author":"Pratumchart","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"B31","article-title":"Widespread subacute cutaneous lupus erythematosus in a patient receiving checkpoint inhibitor immunotherapy with ipilimumab and nivolumab","volume":"25","author":"Kosche","year":"2019","journal-title":"Dermatol Online J"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2007.02.032","article-title":"Lupus induit par le paclitaxel [Paclitaxel-induced lupus","volume":"36","author":"Lortholary","year":"2007","journal-title":"Presse Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3747\/co.20.1546","article-title":"Drug-induced subacute cutaneous lupus erythematosus associated with nab-paclitaxel therapy","volume":"20","author":"Lamond","year":"2013","journal-title":"Curr Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2007.00313.x","article-title":"Paclitaxel-induced cutaneous lupus erythematosus in patients with serum anti-SSA\/Ro antibody","volume":"34","author":"Adachi","year":"2007","journal-title":"J Dermatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/jdv.14053","article-title":"S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)","volume":"31","author":"Kuhn","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007478.pub2","article-title":"Interventions for cutaneous disease in systemic lupus erythematosus","volume":"3","author":"Hannon","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102707","article-title":"Guideline for the diagnosis, treatment and long-term management of cutaneous lupus erythematosus","volume":"123","author":"Lu","year":"2021","journal-title":"J Autoimmun"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1159\/000520297","article-title":"Trichoscopic signs in dermatomyositis, systemic lupus erythematosus, and systemic sclerosis: A comparative study of 150 patients","volume":"238","author":"Chanprapaph","year":"2022","journal-title":"Dermatology"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.045","article-title":"BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors","volume":"82","author":"Hasan Ali","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2020.1805316","article-title":"New insights into the progression from cutaneous lupus to systemic lupus erythematosus","volume":"16","author":"Zhou","year":"2020","journal-title":"Expert Rev Clin Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1539373\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T07:13:38Z","timestamp":1743146018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1539373\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2025.1539373"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1539373","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"article-number":"1539373"}}